Recent Analysts’ Ratings Updates for Tenax Therapeutics (TENX)

Tenax Therapeutics (NASDAQ: TENX) has recently received a number of price target changes and ratings updates:

• 7/2/2026 – Tenax Therapeutics had its “buy” rating reaffirmed by Chardan Capital. They now have a $27.00 price target on the stock.
• 6/30/2026 – Tenax Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/24/2026 – Tenax Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $35.00 price target on the stock.
• 6/22/2026 – Tenax Therapeutics had its “buy” rating reaffirmed by Guggenheim. They now have a $40.00 price target on the stock, up from $34.00.
• 6/22/2026 – Tenax Therapeutics is now covered by Chardan Capital. They set a “buy” rating and a $27.00 price target on the stock.
• 6/12/2026 – Tenax Therapeutics had its price target raised by Piper Sandler from $20.00 to $50.00. They now have an “overweight” rating on the stock.
• 6/1/2026 – Tenax Therapeutics had its “overweight” rating reaffirmed by Piper Sandler.

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.